Profile
Patrice P.
Denefle worked as the Chief Scientific Officer at Genethon and 4P-Pharma.
He also served as the Chief Scientific Officer at Centogene NV from 2021 to 2023.
Dr. Denefle completed his undergraduate degree at Université De Lille.
Former positions of Patrice P. Denefle
| Companies | Position | End |
|---|---|---|
| CENTOGENE N.V. | Chief Tech/Sci/R&D Officer | 30/06/2023 |
| 4P-Pharma | Chief Tech/Sci/R&D Officer | - |
Genethon
 Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Chief Tech/Sci/R&D Officer | - |
Training of Patrice P. Denefle
| Université De Lille | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CENTOGENE N.V. | Commercial Services |
| Private companies | 2 |
|---|---|
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Health Technology |
| 4P-Pharma | Commercial Services |
- Stock Market
- Insiders
- Patrice P. Denefle
